Drug Safety Issues in Therapy COVID-19

One of the serious problems of modern Health care is a new coronavirus infection — COVID-19, which has been declared a global pandemic by the World Health Organization and has covered more than 190 countries. Despite the measures has been taken to limit contacts between people and isolate patients with suspected coronavirus infection, the number of cases grows exponentially every day. Leading laboratories are working on a vaccine, but according to some optimistic forecasts, it may be available no earlier than 11-12 months. According to published data on attempts using various drug regimens in clinical trials, methodological manuals and clinical guidelines for patient management are constantly being developed and updated depending on the severity of the condition. The appointment of a number of drug combinations should be carried out taking into account the definition of an individual assessment of the benefits and risks, because there is ample evidence of serious side effects.

More serious lung tissue lesions are characteristic of patients of an older age group (over 60 years old) with the presence of concomitant diseases, such as cardiovascular, cerebrovascular, diabetes mellitus and obesity, diseases of the bronchopulmonary system and kidneys, which implies taking basic therapy in a constant mode. The appointment of a number of drug combinations should be carried out taking into account the definition of an individual assessment of the benefits and risks, because there is enough evidence of serious side effects, such as the QT interval prolongation, hepatotoxicity, adverse events from the central nervous system. It is necessary to evaluate the interaction of drugs used to treat infections caused by the COVID-19 virus with drugs used in outpatient practice.

1. Colson P., Rolain J.M., Lagier J.C. et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932.

2. Dayer M.R., Taleb-Gassabi S., Dayer M.S. Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study. Arch Clin Infect Dis. 2017;12(4):e13823. doi: 10.5812/archcid.13823.

3. De Meyer S., Bojkova D., Cinatl J. et al. Lack of Antiviral Activity of Darunavir against SARS-CoV-2. 2020. 08 Apr. Preprint from medRxiv. doi: 10.1101/2020.04.03.20052548.

4. Muralidharan N., Sakthivel R., Velmurugan D. et al. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19. J Biomol Struct Dyn. 2020. Apr 06. Preprint. doi: 10.1080/07391102.2020.1752802.

5. Li G., De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature reviews drug discovery. 2020;19(3):149-150. doi:10.1038/d41573-020-00016-0.

6. Zhang C., Huang S., Zheng F. et al. Controversial treatments: An updated understanding of the coronavirus disease 2019. J Med Virol. 2020 Mar 26:10.1002/jmv.25788. doi: 10.1002/jmv.25788. Epub ahead of print.

7. Ko W.C., Rolain J.M., Lee N.Y. et.al. Arguments in favor of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933.

8. Gautret P., Lagier J.C., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. doi: 10.1016/j.ijantimicag.2020.105949.

9. Sheahan T.P., Sims A.C., Leist S.R. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6.

10. Zhang C., Wu Z., Li J.W. et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;105954. doi: 10.1016/j.ijantimicag.2020.105954.

11. Yamamoto M, Matsuyama S, Li X, et al. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. Antimicrob Agents Chemother. 2016;60(11):6532-9. doi:10.1128/AAC.01043-16.

12. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020. 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052.

13. Xu J., Shi P.Y., Li H. et al. Broad-Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. 2020;6(5):909-15.doi: 10.1021/acsinfecdis.0c00052.

14. Richardson P., Griffin I., Tucker C. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31.doi: 10.1016/S0140-6736(20)30304-4.

15. H. Chen, Z. Zhang, L. Wang. First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients. 2020;03.22.20034041. doi: 10.1101/2020.03.22.20034041.

16. Liu, Y.; Chan, W.; Wang, Z. et al. Ontological and Bioinformatic Analysis of Anti-Coronavirus Drugs and Their Implication for Drug Repurposing against COVID-19. Preprints 2020, 2020030413. doi: 10.20944/preprints202003.0413.v1.

17. Zhang J., Ma X., Yu F. et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv 2020.02.05.935387; doi: 10.1101/2020.02.05.935387.

18. Grein J., Ohmagari N., Shin D. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. [published online ahead of print, 2020 Apr 10]. N Engl J Med. 2020;NEJMoa2007016. doi: 10.1056/NEJMoa2007016.

19. Ministry of Health of the Russian Federation. Temporary guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)», version 6 (28.04.20). [Electronic resource]. URL: https: //static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_MR_COVID-19_v6.pdf (date of the application: 17.04.2020). [in Russian].

20. Temporary recommendations for the prevention, diagnosis and treatment of coronavirus infection caused by SARS-CoV-2 of the Moscow Department of Health, 2020. [Electronic resource]. URL: https://mosgorzdrav.ru/ru-RU/professional/scientific-activity/methodical.html. (date of the application: 17.04.2020). [in Russian].

21. Academy of Postgraduate Education FSBI FNCs FMBA of Russia. New coronavirus infection (COVID-19): etiology, epidemiology, clinic, diagnosis, treatment and prevention Training manual. 2020. [Electronic resource]. URL: http://www.medprofedu.ru/upload-files/koronoviruc20.pdf. (date of the application: 17.04.2020). [in Russian].

22. Tisdale J.E., Jaynes H.A., Kingery J.R., et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-87. doi: 10.1161/circoutcomes.113.000152.

23. Tomaselli Muensterman E., Tisdale J.E. Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review. Pharmacotherapy. 2018;38(8):813-21. doi: 10.1002/phar.2146.

24. Tisdale J.E., Jaynes H.A., Kingery J.R. et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381-90. doi: 10.1161/circoutcomes.113.000651.

25. Bitta M.A., Kariuki S.M.0, Mwita C. Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis. Wellcome Open Res. 2017; 2:13. doi: 10.12688/wellcomeopenres.10658.2.

26. Marmor M.F., Kellner U., Lai T.Y. et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058.

27. Melles R.B., Marmor M.F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453-60. doi: 10.1001/jamaophthalmol.2014.3459.

28. Shroyer N.F., Lewis R.A., Lupski J.R. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: Is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol. 2001 ;131(6):761-6. doi: 10.1016/s0002-9394(01)00838-8.

29. Lee J.Y., Vinayagamoorthy N., Han. K. et al. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2016;68(1):184-90. doi: 10.1002/art.39402.

30. Pasaoglu I., Onmez F.E. Macular toxicity after shortterm hydroxychloroquine therapy. Indian J Ophthalmol. 2019;67(2):289-92. doi:10.4103/ijo.IJO_732_18.

31. Hernandez Bel L., Monferrer Adsuara C., Hernandez Garfella M. et al. Cervera Taulet E. Early macular toxicity following 2 months of hydroxychloroquine therapy. Arc Soc Esp Oftalmol. 201893(3):e20-1. doi: 10.1016/j.oftal.2017.12.004.

32. Alanazi M.Q. Drugs may be induced methemoglobinemia. J Hematol Thrombo Dis. 2017;5(3):1-5. doi: 10.4172/2329-8790.1000270.

33. El-Solia A., Al-Otaibi K., Ai-Hwiesh A.K. Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis. BMJ Case Rep. 2018;2018:bcr2017223639. doi: 10.1136/bcr-2017-223639.

34. Unubol M., Ayhan M., Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol. 2011 ;17(1):46-7. doi: 10.1097/RHU.0b013e3182098e1f.

35. Moseley R.H. Macrolide antibiotics. Hepatotoxicity of antimicrobials and antifungal agents. In Drug-induced Liver Disease. 3rd ed. Amsterdam: Elsevier. 2013; pp. 466-7.

36. Longo G., Valenti C., Gandini G. et al. Azithromycin-induced intrahepatic cholestasis. Am J Med. 1997;102(2):217-8.

37. Owens R.C. Jr., Nolin T.D. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43(12):1603-11. doi: 10.1086/508873.

38. Ray W.A., Murray K.T., Hall K. et al. Azithromycin and the Risk of Cardiovascular Death. New England Journal of Medicine. 2012;366(20):1881—90. doi:10.1056/nejmoa1003833.

39. Ryom L., Mocroft A., Kirk O. et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207(9):1359-69. doi: 10.1093/infdis/jit043.

40. Mocroft A., Lundgren J.D., Ross M. et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. The Lancet HIV. 2016;3(1):e23-32. doi:10.1016/S2352-3018(15)00211-8.

41. Shafi T., Choi M.J., Racusen L.C. et al. Ritonavir-induced acute kidney injury: kidney biopsy findings and review of literature. Clin Nephrol. 2011 ;75(Suppl 1):60-4. doi: 10.5414/cn106469.

42. Izzedine H., Harris M., Perazella M.A. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10):563-73. doi: 10.1038/nrneph.2009.142.

43. Chughlay M.F., Njuguna C., Cohen K. et al. Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. AIDS. 2015; 29(4):503-4. doi: 10.1097/QAD.0000000000000563.

44. Fichtenbaum C.J., Gerber J.G., Rosenkranz S.L. et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002; 16(4):569-77. doi: 10.1097/00002030-200203080-00008.

45. Baeza M.T., Merino E., Boix V. et al. Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS. 2007;21(1):119-20. doi:10.1097/qad.0b013e3280117f6f.

46. Noor M.A., Parker R.A., O'Mar E. et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004; 18(16):2137-44. doi:10.1097/00002030-200411050-00005.

47. Rose-John S., Winthrop K., Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399-409. doi: 10.1038/nrrheum.2017.83.

48. Hunter C., Jones S. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015; 16(5):448-57. doi: 10.1038/ni.3153.

49. Campbell L., Chen C., Bhagat S.S., et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552-62. doi:10.1093/rheumatology/keq343.

50. McCarty D., Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(3):61-7. doi: 10.1177/1759720X17752037.

51. Schiff M.H., Kremer J.M., Jahreis A. et al. Integrated safety in tocilizumab clinical trials. Arthritis Research & Therapy. 2011;13(5):R141. doi:10.1186/ar3455.

52. Pardeo M., Wang J., Ruperto N. et al. Neutropenia During Tocilizumab Treatment Is Not Associated With Infection Risk in Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis. J Rheumatol. 2019;46(9):1117-26. doi:10.3899/jrheum.180795.

53. Emery P, Rondon J, Parrino J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(5):849-58. doi:10.1093/rheumatology/key361.

54. Pawar A., Desai, R.J., Solomon D.H. et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019;78(4):456-64. doi: 10.1136/annrheumdis-2018-214367.

55. Boyce, E.G., Rogan, E.L., Vyas D. et al. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis. Ann Pharmacother. 2018;52(8): 780-91. doi: 10.1177/1060028018761599.

56. Vallabhaneni S., Chiller T.M. Fungal Infections and New Biologic Therapies. Curr Rheumatol Rep. 2016;18(5):29. doi: 10.1007/s11926-016-0572-1.

57. Schiff M.H., Kremer J.M., Jahreis A. et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141. doi:10.1186/ar3455.

58. Winthrop K.L., Mariette X., Silva J.T. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018; 24(Suppl 2):S21 -40. doi: 10.1016/j.cmi.2018.02.002.

59. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. 2012. [Electronic resource]. URL: https://pubmed.ncbi.nlm.nih.gov/31643176/

60. Flaig T., Douros A., Bronder E. et al. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2016; 41(6):718-21. doi: 10.1111/jcpt.12456.

61. Gout T., Ostor A.J., Nisar M.K. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol. 2011;30(11):1471-4. doi: 10.1007/s10067-011-1827-x.

62. Peura D. Stress-related mucosal damage. Clin Ther. 1986; 8(A):14-23.

63. Curtis J.R., Lanas A., John A. et al. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(12):1819-28. doi: 10.1002/acr.21764.

64. Pfeil J., Grulich-Henn J., Wenning D. et al. Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab. Rheumatology. 2014;53(9):1713-4. doi: 10.1093/rheumatology/keu032.

65. Xie, F., Yun, H., Bernatsky, S. et al. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis & Rheumatology, 2016;68(11):2612-7. doi: 10.1002/art.39761.

66. Kappos L., Polman C.H., Freedman M.S. et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-9. doi:10.1212/01.wnl.0000237641.33768.8d.

67. Manfredi G., Kotzalidis G.D., Sani G. et al. Persistent interferon-|3-1b-induced psychosis in a patient with multiple sclerosis. Psychiatry and Clinical Neurosciences. 2010;64(5):584-6. doi:10.1111/j.1440-1819.2010.02122.x.

68. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD). 2012. Beta Interferon. [Updated 2018 May 4]. URL: https://www.ncbi.nlm.nih.gov/books/NBK548080/,

69. Winthrop K., Genovese M., Harigai M. et al. Serious infection and associated risk factors in patients with moderate to severe rheumatoid arthritis treated with baricitinib. Oral Presentations. 2017. [Electronic resource]. URL: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf

70. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): 2012. Baricitinib. [UpdatedOct 20]. [Electronic resource]. URL: https://www.ema. europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf.

71. Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5):1094-9. doi: 10.1111/jth.14817.

72. Ahmed I., Majeed A., Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575-82. doi: 10.1136/pgmj.2007.059188.

73. Lee G.M., Arepally G.M. Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):541-63. doi: 10.1016/j.hoc.2013.02.001.

74. Lubenow N., Hinz P., Thomaschewski S. et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010; 115(9):1797-803. doi: 10.1182/blood-2009-07-231506.

75. Prandoni P., Siragusa S., Girolami B.. et al. BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005;106(9):3049-54. doi: 10.1182/blood-2005-03-0912.

76. Testa S., Prandoni P., Paoletti O. et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. J Thromb Haemost. 2020. Online ahead of print. doi: 10.1111/jth.14871.

77. Li M.Y., Li L., Zhang Y. et al. Expression of the SARS-CoV-2 cell receptor gene ACE in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45. doi: 10.1186/s40249-020-00662-x.

78. Ferrario C.M., Jessup J., Chappell M.C. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605-2610. doi:10.1161/CIRCULATIONAHA.104.510461.

79. Bavishi C., Maddox T.M., Messerli F.H. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020. Online ahead of print. doi:10.1001/jamacardio.2020.1282.

80. Zhang H., Penninger J.M., Li Y. et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4):586-90. doi: 10.1007/s00134-020-05985-9.